Novartis Must Note Blood Pressure Drug Risks On EU Labels

Law360, New York (February 17, 2012, 7:00 PM ET) -- A European regulator warned on Friday that Novartis AG’s blood pressure drug Rasilez should not be prescribed to certain patients with Type 1 or Type 2 diabetes or kidney problems, and called for warnings to be included in the labeling of such medications in the European Union.

The European Medicines Agency said its review of Novartis' aliskiren-containing medications, including Rasilez, had shown that they should not be prescribed to patients taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers if they have diabetes or kidney impairment...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required